Key result
Ever use of angiotensin receptor blockers was not associated with an increased rate of cancer overall compared to diuretics and/or beta-blockers (RR 1.00).
Why the study?
Does the use of angiotensin receptor blockers (ARBs) increase the risk of lung, colorectal, breast, or prostate cancer in patients treated with antihypertensive agents?
Population
1,165,781 patients prescribed an antihypertensive agent between 1995 and 2008 in the UK General Practice…
Comparison
Ever use of angiotensin receptor blockers (ARBs) vs Ever use of diuretics and/or beta-blockers
Design
Cohort
Follow-up
mean 6.4 years
Authors
Loading...
Supports no increased overall cancer risk with ARBs in this cohort; hypothesis-generating and requires randomized confirmation.
Cohort (n=1,165,781)
Does the use of angiotensin receptor blockers (ARBs) increase the risk of lung, colorectal, breast, or prostate cancer in patients treated with antihypertensive agents?
Relative Risk: 1 (95% CI 0.96–1.03)
Long-term use of ARBs does not increase the overall risk of the four most common cancers compared to diuretics and/or beta-blockers.
Azoulay et al. (2012) conducted a cohort in Hypertension (n=1,165,781). Angiotensin receptor blockers (ARBs) vs. Diuretics and/or beta-blockers was evaluated on Overall incidence of lung, colorectal, breast, and prostate cancers (RR 1.00, 95% CI 0.96-1.03). Ever use of angiotensin receptor blockers was not associated with an increased rate of cancer overall compared to diuretics and/or beta-blockers (RR 1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: